Rituximab zur Behandlung von Antikörpern (Inhibitoren) bei Personen mit angeborener schwerer Hämophilie
Referencias
Additional references
Borker A, Choudhary N. Rituximab. Indian Pediatrics 2011;48(8):627‐32.
Carcao M, St Louis J, Poon MC, Grunebaum E, Lacroix S, Stain AM, et al. on behalf of the Inhibitor Subcommittee of the Association of Hemophilia Clinic Directors of Canada. Rituximab for congenital hemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006;12(1):7‐8.
Collins PW, Mathias M, Hanley J, Keeling D, Keenan R, Laffan M, et al. Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. Journal of Thrombosis and Haemostasis 2009;7(5):787‐94.
Cooper N, Khair K, Mathias M, Leisner RI. Rituximab is effective and well tolerated in children with hemophilia and factor VIII inhibitors. Blood 2006;108:Abstract no: 1031.
Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence‐based achievements, old and new challenges. Seminars in Thrombosis and Hemostasis 2012;38(1):79‐94.
DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007;13 Suppl 1:1‐22.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34.
Food, Drug Administration. Highlights of Prescribing Information (Rituxan). www.accessdata.fda.gov/drugsatfda_docs/label/2013/103705s5409lbl.pdf (accessed 21 Augest 2013).
Fox RA, Neufeld EJ, Bennett CM. Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia 2006;12(3):218‐22.
Franchini M, Mengoli C, Lippi G, Targher G, Montagnana M, Salvagno GL, et al. Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients analysis. Haemophilia 2008;14(5):903‐12.
Giulino LB, Bussel JB, Neufeld EJ, Pediatric and Platelet Immunology Committees of the TMH Clinical Trial Network. Treatment with rituximab in benign and malignant hematologic disorders in children. Journal of Pediatrics 2007;150(4):338‐44, 344. e1.
Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment‐related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007;109(11):4648‐54.
Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Recombinant versus plasma‐derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007;109(11):4693‐7.
Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013;121(20):4046‐55.
Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens‐Donadel S, et al. Factor VIII products and inhibitor development in severe hemophilia A. New England Journal of Medicine 2013;368(3):231‐39.
Grace RF, Bennett CM, Ritchey AK, Jeng M, Thornburg CD, Lambert MP, et al. Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatric Blood & Cancer 2012;58(2):221‐5.
Hay CR, DiMichele DM, on behalf of the International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012;119(6):1335‐44.
Higgins JPT, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins JPT, Deeks JJ, Altman DG, editor(s). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review. Journal of Thrombosis and Haemostasis 2010;8(6):1256‐65.
Iorio A, Matino D, D'Amico R, Makris M. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database of Systematic Reviews 2010, Issue 8. [DOI: 10.1002/14651858.CD004449.pub3]
Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding‐related complications in people with hemophilia A or B. Cochrane Database of Systematic Reviews 2011, Issue 9. [DOI: 10.1002/14651858.CD003429.pub4]
Kavcic M, Fisher BT, Seif AE, Li Y, Huang YS, Walker D, et al. Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States. Journal of Pediatrics 2013;162(6):1252‐8.
Kobayashi R, Sano H, Suzuki D, Kishimoto K, Yasuda K, et al. Successful treatment of immune tolerance induction with rituximab in a patient with severe hemophilia B and inhibitor. Blood Coagulation and Fibrinolysis 2015;26(5):580‐2.
Kuzmanovic M, Jurisic V. Rituximab for treatment of autoimmune hemolytic anemia. Indian Pediatrics 2012;49(8):672‐4.
Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, et al. Anti‐inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. New England Journal of Medicine 2011;365(18):1684‐92.
Mateo J, Badell I, Forner R, Borrell M, Tizzano E, Fontcuberta J. Successful suppression using Rituximab of a factor VIII inhibitor in a boy with severe congenital haemophilia: an example of a significant decrease of treatment costs. Thrombosis and Haemostasis 2006;95(2):386‐7.
Moschovi M, Aronis S, Trimis G, Platokouki H, Salavoura K, et al. Rituximab in the treatment of high responding inhibitors in severe haemophilia A. Haemophilia 2006;12(1):95‐9.
NCT01064284. Survey of inhibitors in plasma‐product exposed toddlers (SIPPET). https://clinicaltrials.gov/ct2/show/NCT01064284 (accessed 27 January 2015).
U.S. National Heart Lung and Blood Institute. What is hemophilia?. http://www.nhlbi.nih.gov/health/health‐topics/topics/hemophilia/ (accessed 18 November 2012).
Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G. Rituximab therapy for juvenile‐onset systemic lupus erythematosus. Pediatric Nephrology 2008;23(3):413‐9.
Pescovitz MD. Rituximab, an anti‐cd20 monoclonal antibody: history and mechanism of action. American Journal of Transplantation 2006;6(5 Pt 1):859‐66.
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Selewski DT, Shah GV, Mody RJ, Rajdev PA, Mukherji SK. Rituximab (Rituxan). American Journal of Neuroradiology 2010;31(7):1178‐80.
Stedman MR, Curtin F, Elbourne DR, Kesselheim AS, Brookhart MA. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2011;40(6):1732‐4.
Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser‐Bunschoten E, et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thrombosis and Haemostasis 1995;73(2):247‐51.
World Federation of Hemophilia. About bleeding disorders‐How are inhibitors diagnosed?. www.wfh.org/en/page.aspx?pid=648 (accessed 18 November 2012).
World Federation of Hemophilia. About bleeding disorders‐Who is at risk of developing inhibitors?. www.wfh.org/en/page.aspx?pid=653 (accessed in 19 Augest 2013).
World Federation of Hemophilia. About bleeding disorders ‐ What are inhibitors?. www.wfh.org/en/page.aspx?pid=651 (accessed 19 August 2013).
Yadav SP, Chinnabhandar C. Rituximab usage in children: a double edged sword. Indian Pediatrics 2012;49(4):335‐6.
References to other published versions of this review
Ir a:
Liu Y, Zhang L, Santoro C, Song J, Rodriguez A, Wang L. Rituximab for treating inhibitors in children with hemophilia. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD010810]
Liu Y, Zhang L, Santoro C, Song J, Rodriguez A, Wang L. Rituximab for treating inhibitors in people with inherited severe hemophilia. Cochrane Database of Systematic Reviews 2015, Issue 4. [DOI: 10.1002/14651858.CD010810.pub2]
Figuras y tablas -
Figure 1
Study flow diagram.
